Dr. Jordi Guardiola is one of the authors of the article on a new treatment on ulcerative colitis published in The New England Journal of Medicine

This is a phase II clinical trial of a new drug, tofacitinib, an oral inhibitor of Janus kinase, which may become an alternative to patients  who do not respond to usual treatments. Currently, the Inflammatory Bowel Disease Unit participates in a phase III trial with this same drug.

2012 October

Notícies relacionades |Noticias relacionadas | Related news

Comments are closed.

Home | eHub | Email